The Medical Insurance Bureau and the Supreme Law have jointly expanded the field of medical bribery cases in the field of credit evaluation system.

Recently, the Supreme People's Court and the State Health Insurance Administration signed a Memorandum of Cooperation on the Exchange and Sharing of Information on Commercial Bribery Cases in the Pharmaceutical Field. the main content of
is to establish a regular notification system of commercial bribery cases in the field of medicine, actively expand the use of judicial results in the field of commercial bribery in the field of medicine prices and recruitment, jointly promote information exchange and sharing at all levels of the system, and continuously deepen cooperation in the management of commercial bribery in the field of medicine.
In accordance with the Opinions of the State Council of the CPC Central Committee on Deepening the Reform of the Medical Security System, the State Health Insurance Administration has actively promoted the establishment of a credit evaluation system for pharmaceutical prices and recruitment, and has recently issued guidance requiring all localities to establish and implement credit evaluation systems by the end of 2020.
On September 16th, the website of the State Medical Security Administration published the Guidance of the State Medical Security Administration on the Establishment of a Credit Evaluation System for Pharmaceutical Prices and Recruitment, which requires provincial medical security departments to guide and supervise the establishment of centralized procurement agencies in their provinces by the end of 2020, and to implement the system of evaluation of pharmaceutical prices and credit for recruitment.
main channels for the record of loss of trust are the active reporting of pharmaceutical enterprises and the disclosure and sharing of legal instruments: 1, pharmaceutical enterprises should take the initiative to report the loss of trust information to the provincial centralized procurement agencies where the loss of trust occurred.
2, provincial centralized procurement agencies regularly comb through the summary of the relevant departments open or shared adjudication documents, administrative penalty decision documents, etc., to collect and verify the information of the pharmaceutical enterprises to be unreponsioned and recorded.
3, the provincial centralized procurement agencies in the daily operation through monitoring, receiving reports and other means, grasp the pharmaceutical enterprises pricing, bidding, performance, marketing and other aspects of the misconduct information and record.
the second point about the source of the record of failure of trust: regularly combing through the summary of the relevant departments open or shared adjudication documents, administrative penalty decision documents, etc.
is only part of, but not all, of the Chinese refereeing instruments published online, so it is particularly important to establish a linkage mechanism.
To this end, the Open Supreme People's Court and the State Health Insurance Administration signed the Memorandum of Cooperation on the Exchange and Sharing of Information on Commercial Bribery Cases in the Pharmaceutical Field, which is to establish a regular notification system for commercial bribery cases in the pharmaceutical field, which will provide a more complete source of information for all regions to set up a credit evaluation platform for recruitment.
on the fight against corruption in medicine, the relevant departments have been deployed for a long time.
, according to incomplete statistics, this is this year, the relevant national ministries issued article 6 of the pharmaceutical anti-corruption heavyweight document.
On February 26, six ministries, including the National Health Care Commission, the State Health Insurance Administration and the State Drug Administration, jointly issued the Opinions on Strengthening Pharmaceutical Management in Medical Institutions to Promote Rational Drug Use, emphasizing three measures: monitoring and clinical comprehensive evaluation of drug use, strengthening the supervision of rational drug use, regulating drug promotion and pharmacy management in public medical institutions.
June 5, the National Health And Safety Commission, the State Health Insurance Administration and other nine ministries jointly issued the "2020 correction of the field of pharmaceutical purchase and sale and medical services in the field of the special governance of the wind";
to carry out special governance to combat the collection of kickbacks by medical institutions practitioners, and to investigate and punish medical institutions and medical personnel for seeking improper benefits and receiving kickbacks by using their practice.
On June 9, the State Drug Administration issued the Measures for the Administration of the Filing of Pharmaceutical Representatives (Trial) (Draft for Comments), clarified the definition and main responsibilities of pharmaceutical representatives, standardized the form of academic promotion activities of pharmaceutical representatives, improved the management process of pre-training and post-mortem supervision of pharmaceutical representatives, and comprehensively removed the grey areas and fuzzy spaces for the management of pharmaceutical representatives.
July 24, the State Health Insurance Administration posted the Guidance on the Establishment of a Credit Evaluation System for Pharmaceutical Prices and Recruitment (Draft for Comments), which was officially released on September 16th.
the purpose of obtaining improper benefits through the non-trust matters listed in the catalogue in the course of pricing, bidding, performance, marketing, etc., it shall be included in the scope of medical price and credit evaluation.
Also on July 24, the National Health and Safety Commission also issued the "National Health and Health Commission Office on the issuance of 2020 medical industry style construction work special action plan notice" also made it clear that from July this year until the end of the year, will focus on the treatment of medical personnel to collect kickbacks, pharmaceutical companies illegal marketing and other acts.
.